STOCK TITAN

Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

LXRX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
44 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
-19.4% close of January 30, 2026
1-year change
+21.9% closing prices, November 17, 2025 to November 17, 2026
1-month change
+17.1% closing prices, October 16, 2026 to November 17, 2026

Company Description

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products for the treatment of human diseases. Classified under pharmaceutical preparation manufacturing within the broader manufacturing sector, the company emphasizes cardiometabolic and neurological conditions, chronic pain, obesity and related metabolic disorders.

According to its public disclosures, Lexicon describes its mission as pioneering medicines that transform patients’ lives. A central element of its research strategy is the Genome5000™ program, a genomics-based target discovery platform through which Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential across a range of diseases. By precisely targeting these proteins, the company aims to discover and develop medicines intended to treat disease safely and effectively.

Core Research and Development Focus

Lexicon reports that it has advanced multiple medicines to market and maintains a pipeline of drug candidates in discovery, clinical and preclinical development. Across its news releases, the company highlights active programs in heart failure, hypertrophic cardiomyopathy (HCM), neuropathic pain, diabetes, obesity, cardiology, metabolism and other indications. Its work spans both small-molecule therapies and targeted approaches derived from its gene science platform.

One of Lexicon’s most visible assets is sotagliflozin, an oral inhibitor of sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). Company communications state that SGLT2 is responsible for glucose and sodium reabsorption by the kidney, while SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes and chronic kidney disease in clinical studies involving approximately 20,000 patients. Lexicon also notes that sotagliflozin is under investigation for hypertrophic cardiomyopathy.

Commercialization and Partnerships

Lexicon states that it has advanced multiple medicines to market, including the heart failure medicine INPEFA®, which the company identifies as a commercial presentation of sotagliflozin for heart failure in the United States. In its financial updates, Lexicon reports revenues from U.S. sales of INPEFA and describes ongoing efforts to support ex-U.S. regulatory and commercial activities through partners.

The company highlights several notable collaborations. It has an agreement with Viatris covering sotagliflozin for all indications outside the U.S. and Europe. Lexicon reports that it has supported Viatris in regulatory filing strategies in multiple markets and has shipped the first commercial order of INPEFA to the United Arab Emirates following regulatory approval there. The company also notes that Viatris has submitted or prepared regulatory applications in additional markets such as Canada, Australia and New Zealand.

Another key relationship is with Novo Nordisk for the investigational obesity candidate LX9851. Lexicon describes LX9851 as a first-in-class, non-incretin, oral, small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) for the treatment of obesity and associated cardiometabolic disorders. The company reports that it entered into an exclusive, worldwide licensing agreement with Novo Nordisk, has completed all IND-enabling studies, and has received an upfront payment and milestone payments, with the potential for additional milestones and tiered royalties on net sales.

Pipeline Highlights

Lexicon’s public communications outline several late-stage and mid-stage programs:

  • Sotagliflozin for heart failure (INPEFA®): Lexicon reports that sotagliflozin is commercially available in the U.S. for heart failure. Data from large clinical programs such as SCORED and SOLOIST-WHF have been presented, including analyses suggesting consistent relative risk reduction in heart failure and major cardiovascular events across age ranges.
  • Sotagliflozin for hypertrophic cardiomyopathy (HCM): The company is conducting the pivotal SONATA-HCM Phase 3 placebo-controlled study, targeting enrollment of 500 patients with obstructive or non-obstructive HCM. Lexicon notes that site initiation has been completed across multiple countries and that enrollment is ongoing.
  • ZYNQUISTA® (sotagliflozin) for type 1 diabetes (T1D): Lexicon describes ZYNQUISTA as a potential adjunct to insulin for glycemic control in adults with type 1 diabetes. The company reports engagement with the U.S. Food and Drug Administration (FDA), submission of new data, and reliance on safety and exposure data from the STENO1 investigator-initiated study conducted by the Steno Diabetes Center in Denmark. Regulatory feedback has indicated that STENO1’s design and data collection methods may provide viable evidence regarding diabetic ketoacidosis incidence and safety for a potential New Drug Application (NDA) resubmission.
  • Pilavapadin (LX9211) for neuropathic pain: Lexicon identifies pilavapadin as an orally delivered, small molecule drug candidate for diabetic peripheral neuropathic pain (DPNP) and other potential indications. The company reports Phase 2 and Phase 2b data (RELIEF-DPN-1 and PROGRESS) and notes that pilavapadin 10 mg produced reductions in average daily pain scores and was generally well tolerated in the PROGRESS study. An End-of-Phase 2 meeting with the FDA has been held, and Lexicon continues partnership discussions aimed at maximizing the global potential of this non-opioid pain therapy.
  • LX9851 for obesity and cardiometabolic disorders: As described in Lexicon’s releases, LX9851 targets ACSL5, an enzyme involved in lipid metabolism. Preclinical research published in the Journal of the Endocrine Society showed that ACSL5 knockout mice and mice treated with ACSL5 inhibitors demonstrated favorable metabolic characteristics, including reduced body fat and preserved lean mass in diet-induced obesity models. Mechanistic work indicated activation of the ileal brake, delayed gastric emptying and decreased food consumption.

Scientific Platform and Therapeutic Areas

Lexicon repeatedly emphasizes its Genome5000™ platform as a differentiating scientific foundation. By systematically studying thousands of genes and identifying more than 100 protein targets with therapeutic potential, the company has built a pipeline spanning:

  • Heart failure and cardiology, including heart failure with preserved ejection fraction (HFpEF) and HCM
  • Neuropathic pain, particularly diabetic peripheral neuropathic pain
  • Obesity and associated cardiometabolic disorders
  • Diabetes and metabolism
  • Other indications where gene-based target validation suggests potential benefit

Lexicon’s communications also reference its role in convening stakeholders around chronic pain and non-opioid therapies, including a roundtable in Washington, D.C., and a white paper titled “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain.” This underscores the company’s stated interest in policy and access issues related to novel non-opioid pain treatments.

Regulatory and Listing Status

Lexicon Pharmaceuticals, Inc. is incorporated in Delaware and lists its common stock on The Nasdaq Capital Market under the ticker symbol LXRX, as reflected in its Form 8-K filings. The company has disclosed interactions with Nasdaq regarding compliance with the minimum $1 bid price requirement for continued listing. In one Form 8-K, Lexicon reports receiving an additional 180-calendar-day period to regain compliance and notes a transfer of its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market. In a subsequent Form 8-K, the company states that it received confirmation from Nasdaq that it had regained compliance with the minimum bid price requirement and that the matter was closed.

These filings indicate that Lexicon remains listed on a Nasdaq market tier and continues to access capital markets, including through an Open Market Sale Agreement with Jefferies LLC for potential at-the-market offerings of common stock under an effective shelf registration statement.

Business Model and Revenue Sources

Based on its public financial updates, Lexicon’s business model combines product commercialization with research and development and strategic collaborations. The company reports revenue from U.S. sales of INPEFA for heart failure and from licensing arrangements such as its agreement with Novo Nordisk for LX9851. It also references milestone payments and potential royalties as part of its partnership structures.

On the expense side, Lexicon highlights research and development spending on clinical programs like PROGRESS (for pilavapadin) and SONATA-HCM (for sotagliflozin), as well as adjustments in selling, general and administrative expenses following strategic repositioning and changes in marketing efforts. The company has communicated an emphasis on prioritizing programs with the greatest potential for patient impact and value creation and on using collaborations to support its pipeline.

Geographic Footprint and Operations

Lexicon identifies The Woodlands, Texas as the location of its principal executive offices in its SEC filings. Its clinical and commercial activities, however, extend beyond a single geography. The company notes that SONATA-HCM sites have been initiated across the United States, Europe and Latin America, and that its partner Viatris is pursuing regulatory submissions for sotagliflozin in multiple markets outside the U.S. and Europe, including the United Arab Emirates, Canada, Australia and New Zealand.

Through conference presentations and participation in global scientific and investor meetings, such as the J.P. Morgan Healthcare Conference, American Heart Association Scientific Sessions, and various healthcare investment conferences, Lexicon positions its programs within international cardiology, endocrinology and pain-management communities.

Engagement with the Medical and Policy Community

Lexicon’s news releases describe an active presence at major scientific congresses. Data on sotagliflozin have been presented at meetings including the European Society of Cardiology, the American Heart Association, the Hypertrophic Cardiomyopathy Society and the Global Cardio Vascular Clinical Trialists Forum. Presentations have covered topics such as cardiac remodeling, major adverse cardiovascular events, adipose tissue distribution in HFpEF patients, and outcomes in diverse patient populations.

In neuropathic pain, Lexicon has presented pilavapadin data at meetings like the European Association for the Study of Diabetes, NEUROdiab and the Arrowhead Pain Therapeutics Summit. The company has also convened a chronic pain roundtable and produced a white paper on access to non-opioid treatments, reflecting its stated interest in both scientific development and policy frameworks that influence patient access.

Stock Considerations for LXRX

For investors researching LXRX stock, the company’s disclosures highlight several structural features that may be relevant to fundamental analysis:

  • A portfolio that includes an approved heart failure medicine (INPEFA, based on sotagliflozin) and multiple late-stage and mid-stage clinical programs.
  • A genomics-driven discovery platform (Genome5000™) that has generated more than 100 protein targets with therapeutic potential.
  • Strategic collaborations with established pharmaceutical companies such as Viatris and Novo Nordisk, with associated licensing revenues, milestones and potential royalties.
  • Ongoing regulatory interactions with the FDA regarding ZYNQUISTA for type 1 diabetes and pilavapadin for diabetic peripheral neuropathic pain.
  • Continued listing on The Nasdaq Capital Market under the LXRX ticker, with documented efforts to maintain compliance with listing standards.

All of these points are drawn from Lexicon’s own news releases and SEC filings. Investors interested in LXRX may review the company’s official filings, press releases and scientific publications for additional detail on clinical data, risk factors and financial performance.

Stock Performance

$1.81
+1.63%
+0.03
Last updated: at
+21.9%
Performance 1 year
$805.4M

Lexicon Pharmaceuticals (LXRX) closed at $1.78 on November 17, 2026. Over the past 12 months, the price has gained 21.9%.

See what a $1,000 investment in LXRX would be worth today

Average down calculator for LXRX

LXRX Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Lexicon Pharmaceuticals has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, earnings date, clinical trial, conferences. View all LXRX news →

Insider Radar

Net Buyers
90-Day Summary
30,064
Shares Bought
0
Shares Sold
1
Transactions
Most Recent Transaction
Exton Michael (Chief Executive Officer) bought 30,064 shares @ $1.66 on November 6, 2026

Insider buying activity at Lexicon Pharmaceuticals over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Lexicon Pharmaceuticals generated $49.8M in revenue in FY2025, retaining a 99.5% gross margin, operating income reached -$48.9M (-98.2% operating margin), and net income was -$50.3M. Diluted earnings per share stood at -$0.14. The company generated -$67.9M in operating cash flow. The current ratio was 4.88, measuring current assets divided by current liabilities.

$49.8M
Revenue (FY2025)
-$50.3M
Net Income (FY2025)
-$67.9M
Operating Cash Flow

Upcoming Events

NOV
18
November 18, 2026 Marketing

Jefferies fireside chat

Fireside chat at Jefferies Global Healthcare Conference in London at 8:00 a.m. GMT; live stream and replay on Lexicon investor Events page.
Q1
2027
Q1 2027 Clinical

Phase 1 completion

Expected completion of LX9851 Phase 1 study in overweight/obese adults (safety, tolerability, PK/PD); initiated Mar 2026.
Q1
2027
Q1 2027 Clinical

SONATA-HCM topline readout

Topline results expected in Q1 2027; SONATA-HCM >50% enrolled
Q1
2027
Q1 2027 Clinical

Phase 1 trial completion

Expected completion of 96-subject Phase 1 LX9851 obesity trial; Novo Nordisk co-sponsor.
Q1
2027
Q1 2027 Clinical

Topline results release

Topline SONATA-HCM results expected in Q1 2027; primary endpoint at Week 26. Sponsor Lexicon to report topline trial outcome.
Q1
2027
Q1 2027 Clinical

SONATA-HCM topline results

Topline results expected for pivotal SONATA-HCM Phase 3 study
Q1
2027
Q1 2027 Clinical

SONATA-HCM results

Top-line results expected for Phase 3 SONATA-HCM trial in Q1 2027; potential impact on label, commercialization and stock.
Q1
2027
Q1 2027 Regulatory

ZYNQUISTA resubmission

Planned resubmission of ZYNQUISTA FDA approval application in Q1 2027 following STENO1 safety milestones and FDA discussions.
JUN
01
June 1, 2027 Financial

Minimum cash covenant effective

Minimum cash covenant becomes effective 2027-06-01 under Hercules facility; could constrain Lexicon's liquidity and borrowing.
MAY
04
May 4, 2030 Financial

Loan facility maturity

Maturity of Hercules loan facility on 2030-05-04; up to $100M capacity, $55M funded at closing; first-lien security.

Lexicon Pharmaceuticals has 10 upcoming scheduled events. The next event, "Jefferies fireside chat", is scheduled for November 18, 2026 (today). 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the LXRX stock price.

Short Interest History

Last 12 Months

Short interest in Lexicon Pharmaceuticals (LXRX) currently stands at 25.9 million shares, down 3.1% from the previous reporting period, representing 5.9% of the float.

Days to Cover History

Last 12 Months

Days to cover for Lexicon Pharmaceuticals (LXRX) currently stands at 14.0 days, up 8.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 4.4 to 17.9 days.

LXRX Company Profile & Sector Positioning

Lexicon Pharmaceuticals (LXRX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing LXRX often look at related companies in the same sector, including Ardelyx, Inc. (ARDX), Rigel Pharmaceuticals Inc. (RIGL), Solid Biosciences Inc. (SLDB), Sagimet Biosciences Inc. (SGMT), and Syndax Pharmaceuticals, Inc. (SNDX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate LXRX's relative position within its industry.

Frequently Asked Questions

The current stock price of Lexicon Pharmaceuticals (LXRX) is $1.81 as of November 18, 2026.

The market cap of Lexicon Pharmaceuticals (LXRX) is approximately $805.4M. Learn more about what market capitalization means .

The FY2025 revenue of Lexicon Pharmaceuticals (LXRX) is $49.8M, from its most recent completed fiscal year.

The FY2025 net income of Lexicon Pharmaceuticals (LXRX) is -$50.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Lexicon Pharmaceuticals (LXRX) is -$0.14 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Lexicon Pharmaceuticals (LXRX) is -$67.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The operating profit margin of Lexicon Pharmaceuticals (LXRX) is -98.2% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Lexicon Pharmaceuticals (LXRX) is 99.5% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Lexicon Pharmaceuticals (LXRX), current assets divided by current liabilities, was 4.88 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Lexicon Pharmaceuticals (LXRX) is $49.5M for FY2025, its most recent completed fiscal year.

The operating income of Lexicon Pharmaceuticals (LXRX) is -$48.9M for FY2025, its most recent completed fiscal year. Learn about operating income.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human diseases. It focuses on areas such as heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes, metabolism and other indications, as described in its public communications.

Genome5000 is Lexicons genomics target discovery platform. The company reports that its scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases, forming the basis for many of its drug discovery and development programs.

Sotagliflozin is an oral inhibitor of SGLT2 and SGLT1 discovered using Lexicons gene science approach. According to the company, it has been studied in approximately 20,000 patients across heart failure, diabetes and chronic kidney disease. Sotagliflozin is commercially available in the U.S. for heart failure as INPEFAae and is being investigated for hypertrophic cardiomyopathy and other cardiometabolic uses.

ZYNQUISTA is Lexicons brand name for sotagliflozin as a potential adjunct to insulin for glycemic control in adults with type 1 diabetes. The company reports that it has submitted additional data to the U.S. Food and Drug Administration and is working with regulators, using safety and exposure data from the STENO1 study, to support a potential resubmission of its New Drug Application.

Pilavapadin, also referred to as LX9211, is an orally delivered, small molecule drug candidate that Lexicon is developing for diabetic peripheral neuropathic pain and other potential indications. The company has reported Phase 2 and Phase 2b data showing reductions in average daily pain scores at a 10 mg dose and has held an End-of-Phase 2 meeting with the FDA.

Lexicon is developing LX9851, a first-in-class, non-incretin, oral, small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) for obesity and associated cardiometabolic disorders. Preclinical data published in the Journal of the Endocrine Society support ACSL5 as a target for obesity and chronic weight management. Lexicon has licensed LX9851 to Novo Nordisk under an exclusive, worldwide agreement.

In its financial updates, Lexicon reports revenue from U.S. sales of INPEFA for heart failure and from licensing agreements such as its arrangement with Novo Nordisk for LX9851. The company also references milestone payments and the potential for tiered royalties on net sales under certain partnerships.

Lexicons common stock is listed on The Nasdaq Capital Market under the ticker symbol LXRX, as stated in its Form 8-K filings. The company has reported receiving an additional compliance period to meet Nasdaqs minimum $1 bid price requirement and later announced that it had regained compliance, with Nasdaq closing the matter.

Lexicon lists its principal executive offices in The Woodlands, Texas, in its SEC filings. This location serves as the companys corporate base while it conducts clinical and commercial activities through trials and partnerships in multiple regions.

Across its news releases, Lexicon highlights ongoing and planned development in heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes, metabolism, cardiology and other indications. These areas reflect targets identified through its Genome5000 program and subsequent preclinical and clinical work.